6.1 Regulatory standpoints and guideline consensus As human safety data are scarce and animal studies suggest reproductive toxicity, regulators currently advise discontinuing GLP-1RAs immediately upon pregnancy confirmation
minor corrections of proper referencing style.
doi: 10.1016/j.neuroscience.2015.03.017 30
shows robust anti-obesity, anti-diabetic, and cardiometabolic effects in preclinical and clinical studies, including significant reductions in body weight, glycemic markers, blood pressure, and lipids 1,3,5
Analysis of FAERS data from 2003 to 2024 showed significant associations between diabetic retinopathy and semaglutide (PRR, 19.43), dulaglutide (PRR, 9.01), and liraglutide (PRR, 4.4) [95]